Uber Technologies [UBER] - Last Close: $68.99
Ride-share magnate Uber just announced it’s allocating $7 billion to its first-ever share buyback program.
The company decided to launch the buyback after one of its most profitable years ever.
UBER is leading the S&P 500 with a 7.4% gain.
My Take: I am not a fan of UBER, but shares have more than doubled over the past 12 months, and this buyback could provide additional price support.
enGene [ENGN] - Last Close: $7.62
This Canadian biotech announced it has agreed to sell 20 million shares of stock at $10 apiece in an over-subscribed private placement.
The transaction represents a 31% premium to ENGN’s Tuesday closing price, and it’s expected to close on Feb. 16th.
ENGN is up 68.5% on over 100K shares traded, so far.
My Take: Prior to today’s move, ENGN was facing resistance at $8 and $12 per share. It could find support at either of these levels if it can maintain its gains.
Inspira Technologies [IINN] - Last Close: $0.96
Shares of this tiny biotech are rallying after announcing its first-ever U.S. patent approval for its orbiting blood oxygenation delivery system.
The system is described as a "a core technology of the revolutionary INSPIRA™ ART500 device" in a company press release.
INN is up 57.2% on nearly 10 million shares traded in the premarket.
My Take: IINN has been trending higher for the past few sessions, and it saw a volume spike yesterday. There could be potential here.
Cogent [COGT] - Last Close: $5.46
Another micro-cap biotech is also surging after announcing an oversubscribed private placement that’s expected to bring in $225 million.
The offering will include 17 million shares of common stock priced at $7.50 per share, representing a 37% premium to COGT’s Tuesday's closing price.
Earlier this week, Needham reiterated a “buy” rating and maintained its $15 price target on this stock.
COGT is up 42.8% on more than 1.5 million shares traded.
My Take: COGT still has an intact trend line, despite a recent pullback. This catalyst could help it regain its form.